FDA approves Viatris' low-dose estrogen weekly patch?

9.0 pts (24h)Health & MedicineWeekly2d

PolymarketComprobar disponibilidadSin KYC2% de comisiónDatos de resolución verificadosCalibración aceptable

Probabilidad implícita actual

Sí 63%-0.1pt

Calidad del mercado

32 / 100

Baja calidad

Volumen 24h

0 €

Liquidez

96,9 €

Baja liquidez

Compra / Venta

39.0% / 87.0%

Spread

48.0 pt

Spread amplio

Cambio 7d

+8.0 pts

Datos de mercado

Actualizado hace 17 minutos

1 jul 26, 6:1430 jul 26, 17:59

Tendencias

Resultado24hProbabilidad

Solo fondos simulados, sin dinero realNo es asesoramiento financiero

Resultado elegido

Yes63%

Apuesta (USDT)

Reglas

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Tendencia de volumen

2 jul20d de datos21 jul

Mercados Relacionados

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$19B: 4%

POLYMARKET

What price will Bitcoin hit July 27-August 2?

16,1 mil €

↓ 62,000: 64%

POLYMARKET

Chipotle chicken burrito price in July 2026

8 mil €

At least $9.76: 96%

KALSHI

Price of NVIDIA B200 compute by Jul 31, 2026?

4,2 mil €

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

4,1 mil €

Above $2.71: 50%

KALSHI

What price will Ethereum hit July 27-August 2?

2,3 mil €

↓ 1,900: 100%

POLYMARKET

Activos en estos temas

EthereumETH$1,881.74-3.63%

BitcoinBTC$63,342.25-3.02%

SolanaSOL$73.21-4.19%

XRPXRP$1.06-4.50%

BNBBNB$566.49-1.25%

DogecoinDOGE$0.0702-3.70%

Noticias Relacionadas

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Reglas

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

FDA approves Viatris' low-dose estrogen weekly patch?

9.0 pts (24h)Health & MedicineWeekly2d

PolymarketComprobar disponibilidadSin KYC2% de comisiónDatos de resolución verificadosCalibración aceptable

Probabilidad implícita actual

Sí 63%-0.1pt

Calidad del mercado

32 / 100

Baja calidad

Volumen 24h

0 €

Liquidez

96,9 €

Baja liquidez

Compra / Venta

39.0% / 87.0%

Spread

48.0 pt

Spread amplio

Cambio 7d

+8.0 pts

Datos de mercado

Actualizado hace 17 minutos

1 jul 26, 6:1430 jul 26, 17:59

Tendencias

Resultado24hProbabilidad

Solo fondos simulados, sin dinero realNo es asesoramiento financiero

Resultado elegido

Yes63%

Apuesta (USDT)

Reglas

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Tendencia de volumen

2 jul20d de datos21 jul

Mercados Relacionados

Will AbbVie Q2 Global Skyrizi net revenues be above __?

0 €

$19B: 4%

POLYMARKET

What price will Bitcoin hit July 27-August 2?

16,1 mil €

↓ 62,000: 64%

POLYMARKET

Chipotle chicken burrito price in July 2026

8 mil €

At least $9.76: 96%

KALSHI

Price of NVIDIA B200 compute by Jul 31, 2026?

4,2 mil €

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

4,1 mil €

Above $2.71: 50%

KALSHI

What price will Ethereum hit July 27-August 2?

2,3 mil €

↓ 1,900: 100%

POLYMARKET

Activos en estos temas

EthereumETH$1,881.74-3.63%

BitcoinBTC$63,342.25-3.02%

SolanaSOL$73.21-4.19%

XRPXRP$1.06-4.50%

BNBBNB$566.49-1.25%

DogecoinDOGE$0.0702-3.70%

Noticias Relacionadas

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Reglas

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs